Pharmaceutical formulations

A pharmaceutical composition for treating ischemic conditions due to the lack of ATP comprising an effective amount of a phosphoenolpyruvate compound of the formula (1A):

• wherein
• R1 and R2 are independently H, alky, alkenyl, alkoxy (except where applied to OR1), cycloalkyl, aryl, or aralkyl and
• Z1 and Z2 are independently OR1, or a pharmacologically acceptable salt thereof together with a pharmaceutically acceptable carrier.

A method of treating an ischemic condition due to lack of ATP comprising administering to a patient an effective amount of a phosphoenolpyruvate compound of the formula (1A):

• wherein
• R1 and R2 are independently H, alky, alkenyl, alkoxy (except where applied to OR1), cycloalkyl, aryl, or aralkyl and Z1 and Z2 are independently OR1, or a pharmacologically acceptable salt thereof.

A method for the treatment or prophylaxis of an ischemic condition due to the lack of ATP selected from the group consisting of myocardial infarction, septic shock, cardiogenic shock and other manifestations where the heart muscle is depleted of ATP, excision of limbs, indications involving neuronal damage due to cerebral ischemia and whose damage is due to peripheral vascular ischemia comprising administering to a patient an effective amount of a phosphoenolpyruvate compound of the formula (1A):

• wherein R1 and R2 are independently H, alky, alkenyl, alkoxy (except where applied to OR1), cycloalkyl, aryl, or aralkyl and Z1 and Z2 are independently OR1, or a pharmacologically acceptable salt thereof.

A method for the treatment or prophylaxis of a condition selected from physical or mental fatigue and circulatory insufficiencies due to the lack of ATP comprising administering to a patient an effective amount of a phosphoenolpyruvate compound of the formula (1A):

• wherein R1 and R2 are independently H, alky, alkenyl, alkoxy (except where applied to OR1), cycloalkyl, aryl, or aralkyl and Z1 and Z2 are independently OR1, or a pharmacologically acceptable salt thereof.

A method of prolonging the viable storage life of stored blood comprising adding thereto an effective amount of a phosphoenolpyruvate compound of the formula (1A):

• wherein R1 and R2 are independently H, alkyl, alkenyl, alkoxy (except where applied to OR1), cycloalkyl, aryl, or aralkyl and Z1 and Z2 are independently OR1, or a pharmacologically acceptable salt thereof.

A pharmaceutical composition comprising an effective amount of a phosphoenolpyruvate compound of the formula (2).

• wherein R1 and R2 are independently H, alkyl, alkenyl, alkoxy, cycloalkyl, aryl, or aralkyl or a pharmacologically acceptable salt thereof together with a pharmaceutically acceptable carrier.

A pharmaceutical composition selected from the group consisting of solid oral dosage units, sterile injection solutions, sterile suspensions, suppositories, lozenges and pastilles and comprising an effective amount of a phosphoenolpyruvate compound of the formula (1A):

• wherein R1 and R2 are independently H, alkyl, alkenyl, alkoxy (except where applied to OR1), cycloalkyl, aryl, or aralkyl and Z1 and Z2 are independently OR1, or a pharmacologically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

A pharmaceutical composition in unit dosage for administration by a route selected from the group consisting of orally and by injection to provide 5 g to 25 g per day of a phosphoenolpyruvate compound of the formula (1A):

• wherein R1 and R2 are independently H, alky, alkenyl, alkoxy (except where applied to OR1), cycloalkyl, aryl, or aralkyl and Z1 and Z2 are independently OR1, or a pharmacologically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

A method for the treatment or prophylaxis of cardiac ischemia comprising administering to a patient an effective amount of a phosphoenolpyruvate compound of the formula (3):